BioMarin’s Momentum Grows With Twin Blockbuster Plans
Dwarfism Drug Data Look Promising
The frontrunner in hemophilia A gene therapy has been hit by data doubts, but this and achondroplasia drug could deliver in 2020.
You may also be interested in...
During BioMarin’s earnings call Feb. 21, CEO Bienaime indicated the company may be looking to price its valoctocogene roxaparvovec gene therapy at $2m-$3m, as it would represent a savings over the annual cost of infused clotting factor therapy.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.